Induction of t-cell responses against PSA by plasmid DNA immunization
Author: Pavlenko, Maxim
Date: 2005-06-10
Location: Cancer Centrum, Karolinskas föreläsningssal, plan 00, Karolinska Universitessjukhuset, Stockholm
Time: 9.00
Department: Institutionen för onkologi-patologi / Department of Oncology-Pathology
View/ Open:
Thesis (649.7Kb)
Abstract
This thesis is focused on using plasmid DNA encoding human prostate-specific antigen (PSA) for immunotherapy of prostate cancer. PSA is a secreted serine protease, which is produced almost exclusively by prostate epithelial cells. It is also expressed by prostate epithelial cells after malignant transformation and thus can be considered a tumor-associated antigen for prostate cancer. In our studies we investigated the potency of DNA vaccines to induce PSA-specific CD8+ cytotoxic T lymphocytes (CTLs), which can efficiently target and eliminate PSA-producing tumor cells.
In the first study we evaluated the efficacy of PSA-encoding plasmid DNA (pVax-PSA) in inducing T cell responses in patients with hormone-refractory prostate cancer. The plasmid DNA was administered during five cycles in doses of 100, 300 and 900μg, with three patients in each cohort. We demonstrated in this study that the pVax-PSA vaccine given in doses of 900μg is safe and can induce cellular immune responses against PSA.
The major aim of the following studies was to characterize the potency of pVax-PSA plasmid in inducing CD8+ T-cell responses in a mouse model. We demonstrated that the pVax-PSA plasmid is highly immunogenic in mice, with just one DNA immunization being sufficient to induce potent CTL responses against PSA. Additional modifications of human PSA, by linking it to heat shock proteins of different origin (pVax-PSA-HSPs plasmids), did not further increased the efficacy of pVax-PSA plasmid in inducing CTL responses or mediating protection against tumor challenge. We have also characterized the epitope specificity of CTLs induced after immunization of C57Bl/6 mice with the pVax-PSA plasmid.
We demonstrated that the majority of PSA-specific CTLs were directed against a single H-2Db-restricted epitope HCIRNKSVIL65-74 of PSA. However, immunization of mice with pVax-PSA plasmid does not properly reflect the clinical settings, where endogenous expression of PSA may potentially lead to depletion of high-avidity CD8+ T cell precursors with PSA-specific reactivity. Nevertheless, our findings in this study, will allow us to address this relevant question in experiments with transgenic mice expressing human PSA in prostate tissue, once such model is available on C57Bl/6 background.
In the last study, we investigated the role of activation of antigen-presenting cells (APCs) by the plasmid DNA backbone in the induction of CTL responses by DNA vaccines. A single immunization with pVax-PSA plasmid induced stronger CTL responses in wild-type than in TLR9- or MyD88-deficient mice. These results suggest that immunostimulatory activity of CpG-DNA is essential for efficient priming of CTLs after a single DNA immunization.
Collectively, our findings demonstrate that DNA vaccines represent a promising modality for induction of PSA-specific T-cell responses. Detailed characterization of immunogenicity of pVax-PSA plasmid in C57Bl/6 mice establishes an experimental background for further evaluation of various strategies to increase its potency in inducing CTL responses in a PSA-transgenic murine model.
In the first study we evaluated the efficacy of PSA-encoding plasmid DNA (pVax-PSA) in inducing T cell responses in patients with hormone-refractory prostate cancer. The plasmid DNA was administered during five cycles in doses of 100, 300 and 900μg, with three patients in each cohort. We demonstrated in this study that the pVax-PSA vaccine given in doses of 900μg is safe and can induce cellular immune responses against PSA.
The major aim of the following studies was to characterize the potency of pVax-PSA plasmid in inducing CD8+ T-cell responses in a mouse model. We demonstrated that the pVax-PSA plasmid is highly immunogenic in mice, with just one DNA immunization being sufficient to induce potent CTL responses against PSA. Additional modifications of human PSA, by linking it to heat shock proteins of different origin (pVax-PSA-HSPs plasmids), did not further increased the efficacy of pVax-PSA plasmid in inducing CTL responses or mediating protection against tumor challenge. We have also characterized the epitope specificity of CTLs induced after immunization of C57Bl/6 mice with the pVax-PSA plasmid.
We demonstrated that the majority of PSA-specific CTLs were directed against a single H-2Db-restricted epitope HCIRNKSVIL65-74 of PSA. However, immunization of mice with pVax-PSA plasmid does not properly reflect the clinical settings, where endogenous expression of PSA may potentially lead to depletion of high-avidity CD8+ T cell precursors with PSA-specific reactivity. Nevertheless, our findings in this study, will allow us to address this relevant question in experiments with transgenic mice expressing human PSA in prostate tissue, once such model is available on C57Bl/6 background.
In the last study, we investigated the role of activation of antigen-presenting cells (APCs) by the plasmid DNA backbone in the induction of CTL responses by DNA vaccines. A single immunization with pVax-PSA plasmid induced stronger CTL responses in wild-type than in TLR9- or MyD88-deficient mice. These results suggest that immunostimulatory activity of CpG-DNA is essential for efficient priming of CTLs after a single DNA immunization.
Collectively, our findings demonstrate that DNA vaccines represent a promising modality for induction of PSA-specific T-cell responses. Detailed characterization of immunogenicity of pVax-PSA plasmid in C57Bl/6 mice establishes an experimental background for further evaluation of various strategies to increase its potency in inducing CTL responses in a PSA-transgenic murine model.
List of papers:
I. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P (2004). A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 91(4): 688-94.
Pubmed
II. Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa P (2004). Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother. 53(12): 1085-92.
Pubmed
III. Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P (2005). Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate. 64(1): 50-59.
Pubmed
IV. Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P (2005). Induction of CTL responses by DNA immunization is improved in TLR9- and MyD88-deficient mice. [Manuscript]
I. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P (2004). A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 91(4): 688-94.
Pubmed
II. Pavlenko M, Roos AK, Leder C, Hansson LO, Kiessling R, Levitskaya E, Pisa P (2004). Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins. Cancer Immunol Immunother. 53(12): 1085-92.
Pubmed
III. Pavlenko M, Leder C, Roos AK, Levitsky V, Pisa P (2005). Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate. 64(1): 50-59.
Pubmed
IV. Pavlenko M, Leder C, Moreno S, Levitsky V, Pisa P (2005). Induction of CTL responses by DNA immunization is improved in TLR9- and MyD88-deficient mice. [Manuscript]
Issue date: 2005-05-20
Rights:
Publication year: 2005
ISBN: 91-7140-385-X
Statistics
Total Visits
Views | |
---|---|
Induction ...(legacy) | 1994 |
Induction ... | 103 |
Total Visits Per Month
October 2023 | November 2023 | December 2023 | January 2024 | February 2024 | March 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
Induction ... | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
File Visits
Views | |
---|---|
thesis.pdf(legacy) | 644 |
thesis.pdf | 120 |
thesis.pdf.txt(legacy) | 2 |
Top country views
Views | |
---|---|
Sweden | 1023 |
United States | 361 |
China | 118 |
Germany | 93 |
United Kingdom | 20 |
Italy | 20 |
Denmark | 18 |
Russia | 18 |
South Korea | 17 |
Finland | 10 |
Top cities views
Views | |
---|---|
Stockholm | 938 |
Sunnyvale | 40 |
Beijing | 38 |
Romeo | 32 |
Nürnberg | 31 |
Kiez | 24 |
Seoul | 16 |
London | 13 |
Ballerup | 12 |
Pisa | 10 |